



Attorney/Docket No. 12964.19
Customer No. 27683

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Hassan Jomaa

Serial No. 09/719,946

Filed: December 15, 2000

For: MEDICAMENTS CONTAINING BISPHOSPHONIC
ACIDS AND DERIVATIVES THEREOF WHICH
ARE PROVIDED FOR PREVENTING AND TREATING
AUTOMIMMUNE DISEASES AND ALLERGIES

§
§ Group Art Unit: 1614
§
§
§ Examiner: Brian Yong S. Kwon
§
§
§
§
§
§

#22
BUEG
2-11-03

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 CFR §1.97 and §1.98, the Examiner's attention is directed to the documents listed on the enclosed modified Form PTO-1449. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. The cited references are listed in alphabetical order and are not in any order based on their pertinence. Copies of the listed information are attached.

Accompanying this transmittal is the \$180.00 fee set forth in 37 CFR §1.17(p) for submission of a Second Supplemental Information Disclosure Statement under §1.97(c)(2). The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account 08-1394.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Respectfully submitted,

Gloria L. Norberg

Gloria L. Norberg
Agent for Applicants
Registration No. 36,706

01/31/2003 CNGUYEN 00000104 09719946

02 FC:1806

180.00 OP

Date: *January 24, 2003*
HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 512-867-8528
Facsimile: 512-867-8632

